KALV vs V · rev $13.7M vs P/E 33, rev $40.00B
Kalvista Pharmaceuticals Inc (KALV) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
Kalvista Pharmaceuticals Inc (KALV) is a biotechnology company listed on NASDAQ.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported KALV revenue for 2025-09-30 was $13.7M. Net income was -$158.9M. KALV currently screens at market cap $1.44B.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
KALV currently screens at market cap $1.44B. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the KALV and V stock pages for the full models.
Not investment advice.